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Human ectopic viral integration site 1 (EVI1) is an
oncogenic transcription factor known to play a crit-
ical role in many aggressive forms of cancer. Its
selective modulation is thought to alter the cancer-
specific gene regulatory networks. Pyrrole-imidazole
polyamides (PIPs) are a class of small DNA binders
that can be designed to target any destined DNA
sequence. Herein, we report a sequence-specific
pyrrole-imidazole polyamide, PIP1, which can target
specific base pairs of the REL/ELK1 binding site
in the EVI1 minimal promoter. The designed PIP1
significantly inhibited EVI1 in MDA-MB-231 cells.
Whole-transcriptome analysis confirmed that PIP1
affected a fraction of EVI1-mediated gene regulation.
In vitro assays suggested that this polyamide can
also effectively inhibit breast cancer cell migration.
Taken together, these results suggest that EVI1-tar-
geted PIP1 is an effective transcriptional regulator
in cancer cells.
INTRODUCTION
Ectopic viral integration site 1 (EVI1) was identified initially as an
integration locus of retroviruses in AKXD myeloid tumor mouse
models (Mucenski et al., 1988). EVI1 is a zinc finger transcrip-
tion regulator encoded in the human chromosome 3q26 that
undergoes frequent rearrangements that can activate EVI1
expression in association with pathogenesis caused by myeloid
leukemia (Morishita et al., 1992). Ectopic viral integration site 1
plays an important role in hematopoietic stem cell proliferation,
and its defects cause deregulated vascularization and neural
development during embryogenesis (Hoyt et al., 1997; Yuasa
et al., 2005). High expression of EVI1 is categorized as a risk fac-
tor for cancer, and several reports have suggested amajor role of
EVI1 in the onset of leukemic, pancreatic, ovarian, and breast
cancers (Brooks et al., 1996; Jazaeri et al., 2010; Lugthart
et al., 2008; Tanaka et al., 2014) regardless of the presence of
a 3q26 rearrangement. EVI1 coordinates with the proto-onco-
gene FOS in regulating gene expression to control numerous
tumorigenic properties like cellular motility, adhesion, and
growth (Bard-Chapeau et al., 2012).1370 Chemistry & Biology 21, 1370–1380, October 23, 2014 ª2014 EAmong the epithelial cancers, breast cancer is the commonly
diagnosed malignancy with increasing mortality rate. Robust
expression and polymorphism of EVI1 has been reported in
breast cancer patients and many breast cancer cell lines (Patel
et al., 2011; Wang et al., 2014), and EVI1 influences the cancer
risk and prognosis in breast cancer patients. EVI1 is the down-
stream target of the tumor suppressor microRNA miR-22, and
the loss of expression of miR-22 leads to the activation of
EVI1-mediated metastasis-specific oncogenic signaling path-
ways, thus contributing to the pathogenesis of breast cancer
cells (Patel et al., 2011). Therefore, development of effectors
capable of the targeted repression of EVI1 could be useful in
counteracting its tumor-promoting property in the treatment of
breast cancer.
The naturally occurring antibiotic distamycin A paved the way
for the development of a class of targeting small molecules
called pyrrole-imidazole (Py-Im) polyamides (PIPs). PIPs can
bind to the DNA minor groove in a sequence-specific mode
and compete with the specific transcription factor in binding to
their respective DNA recognition sequences. Therefore, polyam-
ides inhibit the DNA-protein interface, causing the modulation in
gene expression (Dervan, 2001; Dickinson et al., 1999; Nickols
and Dervan, 2007; Trauger et al., 1996; Willis and Arya, 2010).
PIPs are synthetic oligomers of N-methylpyrrole and N-methyli-
midazole that have easy access to cells without the need for a
precise delivery system (Bando et al., 2002; Best et al., 2003;
Murty and Sugiyama, 2004). PIPs are unaffected by nucleases
and are relatively stable inside cells. The pyrrole of PIP prefers
binding to T, A, and C bases, whereas the imidazole favors
only the G base. Thus, side-by-side pairings of Im/Py and
Py/Im in a hairpin bind to G,C and C,G, respectively, whereas
Py/Py pairing binds to A,T or T,A. A g-aminobutyric acid turn
in a hairpin PIP selectively prefers A/T, and the paired b-alanine
residue (b/b) favors A,T or T,A binding (Bando et al., 2002; Der-
van, 2001; Matsuda et al., 2006; Trauger et al., 1996). A hairpin
PIP (N to C terminus) generally prefers binding in the 50-30 direc-
tion of the DNA strand, termed ‘‘forward orientation’’ (White
et al., 1997). However, recent studies employing high throughput
Bind-n-Seq analysis revealed the N to C aligning of polyamides
also in the 30-50 direction of the DNA strand, termed ‘‘reverse
orientation.’’ However, the binding affinity and the orientation
preference of the polyamides seem to be completely dependent
on its structure-activity relationship that remains to be unsolved
(Kang et al., 2014; Meier et al., 2012b).
The ability to regulate gene expression suggests the possible
use of hairpin polyamides in medical therapeutics. PIPslsevier Ltd All rights reserved
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Figure 1. Design of Pyrrole-Imidazole
Polyamides
(A) Structures of match polyamide PIP1 and
mismatch polyamide PIP2. Pyrrole and
imidazole are shown as open and closed circles,
respectively.
(B) Schematic representation of the binding of
match Py-Im polyamide PIP1 in forward orienta-
tion (N- to C-terminal in 50-30 direction) to the
REL/ELK1 target sequences in the EVI1 minimal
promoter.
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Py-Im Polyamide Targeted to EVI1 Oncogenedesigned to bind to the AP-1-binding sequence have been
shown to bind to the promoter region of TGF-b gene and
to reduce TGF-b expression, resulting in improved treatment
of progressive renal disease in rat models (Matsuda et al.,
2006). The potential application of hairpin polyamides as
antitumor agents is a major subject of interest, and several
studies have focused on this aspect. Polyamides modulate
the expression of downstream genes regulated by androgen,
glucocorticoid, and estrogen in cell culture when targeted to
their respective consensus response elements (Muzikar et al.,
2009; Nickols and Dervan, 2007; Nickols et al., 2013). Hairpin
polyamides targeted to the 50-WGWWCW-30 sequence signifi-
cantly reduce tumor growth in mouse xenograft models (Yang
et al., 2013). These studies have indicated that polyamides tar-
geted to the gene promoter region may act as an effective gene
silencer.
Encouraged by these previous findings, we aimed to produce
a hairpin polyamide that could target and inhibit EVI1 expression
in the breast cancer cell line MDA-MB-231. Here we show that
our synthetic PIP1 targeting the position overlapping the RELChemistry & Biology 21, 1370–1380, October 23, 2014 ªand ELK1 recognition sequences in the
minimal promoter region of EVI1 modu-
lates the expression of EVI1. Using
genome-wide expression analysis, we
found that PIP1 could modulate the
downstream targets of EVI1 and the
migration of MDA-MB-231 cells. This
work reports the ability of a synthetic
small molecule to target EVI1. This strat-
egy could be expanded to target critical
oncogenic transcription factors of thera-
peutic importance.
RESULTS
Design of PIPs
ELK1, a member of the ETS family of tran-
scription factors, is one of the major regu-
lators of EVI1 expression (Maicas et al.,
2013). Targeting the key sequences like
the ELK1 recognition sequence on the
promoter region of the therapeutically
important factor like EVI1 could be an effi-
cient way of controlling its expression. In
order to obtain the specificity in targeting
a particular gene promoter, polyamideshave to be designed to cover the boundary that span the
consensus sequence recognized by the transcription factor
(Matsuda et al., 2006). Specificity toward EVI1 promoter could
be achieved by designing PIPs that cover the overlapping se-
quences recognized by ELK1 and REL on the human ectopic
viral integration site 1 minimal promoter. Such a strategy of tar-
geting overlapping sequences has the advantage of controlling
both ELK1 and REL mediated regulation of EVI1 expression.
Two nine-base pair-recognizing hairpin PIPs were designed
and synthesized to study their effect on the expression of EVI1.
We incorporated b/b in the structure of our PIPs because our
previous studies have shown that the replacement of pyrrole
with b-alanine increases the binding affinity of PIPs to the target
DNA sequence (Han et al., 2013). PIP1 was anticipated to bind
in the forward orientation 50-30 to the targeted REL and ELK1
overlapping bases of the ectopic viral integration site 1 minimal
promoter. To substantiate the sequence specificity, PIP2 was
designed as a negative control with a single mismatch (a single
pyrrole replaced by an imidazole, which interrupts the binding
to the match site). Figure 1A shows the structure of the PIP12014 Elsevier Ltd All rights reserved 1371
Figure 2. Effect of Polyamide Targeting on Human EVI1 Promoter
Activity and EVI1 mRNA Expression
(A) MDA-MB-231 cells were transfected with pMCS-Cypridina luciferase
vector carrying a human EVI1 gene promoter insert and treated with DMSO,
PIP1, and PIP2 at 2 mm concentration. After 48 hr, EVI1 promoter activity was
measured with the luciferase assay (p < 0.01 versus control).
(B) Expression level of EVI1 mRNA after match forward binding (PIP1) and
mismatch (PIP2) treatment in MDA-MB-231 cells by qRT-PCR. The relative
expression level of EVI1 mRNA normalized to b-actin is shown (p < 0.05
with respective to the control DMSO). Data are represented as mean ± SEM
(n = 3).
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Py-Im Polyamide Targeted to EVI1 Oncogeneand PIP2, and Figure 1B depicts the binding of the polyamide
matched to its target sequences.
Effect of PIPs on EVI1 Promoter Activity
We first measured the luciferase activity of the designed PIPs in
MDA-MB-231 cells transfected with the human ectopic viral
integration site 1 promoter to verify their inhibitory effect.
Match hairpin PIP1 significantly repressed the promoter activity
by reducing the luciferase emission at 2 mM concentration
compared with the control DMSO. By contrast, the mismatch
PIP2 (also at 2 mM) had no effect on luciferase activity (Figure 2A).1372 Chemistry & Biology 21, 1370–1380, October 23, 2014 ª2014 EQuantification of EVI1 mRNA in PIP-Treated
MDA-MB-231 Cells
We next performed quantitative RT-PCR (qRT-PCR) to confirm
whether the expression of human ectopic viral integration site
1 mRNA could be modulated by the designed PIPs. The expres-
sion level of ectopic viral integration site 1 was significantly in-
hibited inMDA-MB-231 cells with increasing final concentrations
of match PIP1 at concentrations of 2 and 10 mm. However, the
mismatch PIP2 (nonsignificant versus control DMSO) did not
reduce theEVI1mRNA level significantly within the effective con-
centration range of the match polyamide. This finding confirmed
the importance of sequence specificity (Figure 2B).
Genome-wide Profiling of EVI1-Regulated Genes by
Match PIPs
We analyzed the global expression changes with the favorable
forward-binding PIP1 to verify the biological significance of
gene repression. EVI1 is a zinc finger transcription factor that co-
ordinates with various coactivators and corepressors, thereby
activating and repressing a large set of functional genes (Izutsu
et al., 2001; Soderholm et al., 1997). We next analyzed the
comprehensive effect of match PIP1 at a concentration of
10 mM on EVI1-regulated genes using an Affymetrix Human
Gene 2.1 ST Array Strip in MDA-MB-231 cells. This array covers
about 53,617 gene transcripts. The generated probe set intensity
files (CEL files) of the array strips were subjected to the Iter-
PLIER algorithm in the core probe set analysis of the Affymetrix
expression console software to evaluate the gene level expres-
sion measurements. The Iter-PLIER algorithm removes probe
sets with unreliable signals and estimates the normalized gene
level signal intensities (Huang et al., 2012) after background sub-
traction in log2scale. To detect the statistically significant
changes between DMSO- and PIP1-treated samples, the
normalized signal intensities were subjected to t test statistics
and the differential expression values were calculated in terms
of log 2 ratio. Compared with the control DMSO-treated cells,
match PIP1 significantly regulated 985 genes by more than
2-fold, of which 738 genes were downregulated and 247 genes
were upregulated (t test, p < 0.05).
We then performed gene set enrichment analysis (GSEA) of
the significant differentially regulated genes (p < 0.05) using the
published gene expression profiles in NFS-60 cells after knock-
ing down EVI1 (Glass et al., 2013) with the gene sets (Table S1
available online). GSEA demonstrated that the genes modulated
by EVI1-targeted PIP1 showed similarity with the defined EVI1
knockdown gene set (Glass et al., 2013). Furthermore, by assign-
ing the cutoff p value to be less than 0.01 and false discovery rate
(FDR) < 0.25, GSEA revealed that the match PIP1 could signifi-
cantly downregulate the genes upregulated by EVI1 when
comparedwith the control DMSO (Figure 3A). TheGSEA-derived
heatmap of the EVI1 upregulated genes in the control DMSO and
PIP1-treated samples is shown in Figure 3B. Signal intensities
are demonstrated by shades of red (upregulation) and blue
(downregulation).We also performed qRT-PCR for PLXNC1
and LOXL3 as representatives from the GSEA top-ranked list
of EVI1 target genes and demonstrated that the expression of
the abovementioned genes were modulated only by match
PIP1 but not bymismatch PIP2 (Figure S1). This finding indicated
the inability of PIP2 to regulate the GSEA-ranked EVI1 targetlsevier Ltd All rights reserved
Figure 3. Gene Set Enrichment Analysis
(A) GSEA to conclude whether genes differentially repressed by EVI1 targeted PIP1 (10 mm) were significantly associated with the investigated gene expression
profiles (Glass et al., 2013). The enrichment score clearly shows that the genes at the top of the ranked list are overrepresented in the reference gene set. NES,
normalized enrichment score; NOM p-val, nominal p value; FDR q-val, false discovery rate q value.
(B) Heatmap of the top ranked genes upregulated in control DMSO (red color) and downregulated in PIP1 samples (blue color), corresponding to the reference
gene set.
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Figure 4. Microarray Analysis of Gene
Expression
(A) Heatmap depicting the effect of match Py-Im
polyamide 1 on the expression pattern of known
EVI1 target genes in the technical duplicates of
whole transcriptome analysis (p < 0.05) regulated
at least 1.2-fold (upregulated value shown in yellow
color and downregulated values represented by
blue color).
(B) Confirming the effect of Py-Im polyamide 1
(10 mm) in MDA-MB-231 cells observed by whole
transcriptome analysis. Relative mRNA levels of
four genes (two upregulated [DUSP1 and SOCS3]
and two downregulated [LTBP1 and LYST])
were investigated using qRT-PCR (p < 0.01 versus
DMSO control). Data are represented as
mean ± SEM (n = 3).
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and that the observed gene expression profile was due to the
modulation by EVI1.
To obtain a deeper insight into the downstream genes differ-
entially regulated by EVI1-targeted PIP1, we next examined the
changes in the expression levels of some of the reported EVI11374 Chemistry & Biology 21, 1370–1380, October 23, 2014 ª2014 Elsevier Ltd All rights restargets (Bard-Chapeau et al., 2012; Glass
et al., 2013; Goyama et al., 2008) and
compared these between the DMSO-
and PIP1-treated microarray expression
profile data using a heatmap. Heatmaps
are employed to display the signal inten-
sities of gene probes in colored cells,
where strong signal intensities (highest
expression value) are represented by yel-
low or red and where blue represents the
weak intensity (lowest expression value),
whereas the intermediate probe expres-
sion values are indicated by varying
shades of yellow/red and blue. This anal-
ysis included the genes that were signifi-
cantly regulated (t test, p < 0.05) by
>1.2-fold by match PIP1. The heatmap
image generated to represent the differ-
entially expressed signatures of the
known EVI1-regulated genes in PIP1-
treated samples relative to the expression
in the control DMSO-treated samples
is shown in Figure 4A. The analysis re-
vealed that match PIP1 downregulated
those genes upregulated by EVI1 and
that PIP1 also upregulated the EVI1-
repressed genes. The genes represented
in the heatmap and their respective fold
changes are shown in Tables 1 and S2.
Some of the representative upregu-
lated genes (DUSP1 and SOCS3) and
downregulated genes (LTBP1 and LYST)
were selected for qRT-PCR to verify the
microarray expression data obtained for
PIP1. The observed results demonstratedthat thematch PIP1 effectively reproduced the gene regulation in
a pattern similar to that of the microarray data, whereas
mismatch PIP2 failed to regulate the EVI1 target genes (Fig-
ure 4B). These results explain that PIP1 gains over the mismatch
PIP2 in the specificity toward targeting EVI1 and its downstream
genes.erved
Table 1. Expression Pattern of EVI1 Downstream Genes
Regulated by PIP1 in MDA-MB-231 Cells
Transcript ID Gene Symbol Fold Changea p < 0.05b
16883675 IL1RL2 3.20025419 0.011043493
16869939 UCA1 3.197761186 0.004433311
16661508 SMPDL3B 2.053481144 0.04528849
16721905 ADM 1.969589943 0.017152285
16929925 GCAT 1.943088619 0.001396785
17013279 STX11 1.933034786 0.009880415
17049779 SH2B2 1.855266966 0.029205669
17110670 PIM2 1.769033048 0.04284442
16929015 OSBP2 1.753892713 0.04055794
16849652 TBC1D16 1.73395493 0.047790155
16863877 PPP1R15A 1.689966678 0.017193692
17089525 LCN2 1.663160961 0.035273492
16849400 SOCS3 1.6559035 0.024376618
16659238 TNFRSF1B 1.646927446 0.000786928
16848873 GALK1 1.639203875 0.023774723
16758130 ORAI1 1.63325154 0.004703509
17062679 IMPDH1 1.616689923 0.01009058
16772942 ZMYM2 1.633062493 0.04165688
16952707 ZNF445 1.638142318 0.001358996
16887702 ITGA6 1.639071739 0.025391394
16805495 IGF1R 1.655426434 0.008250059
16869596 LPHN1 1.690483225 0.004838508
16961331 MECOM 1.723875995 0.042155035
16806249 OCA2 1.88105574 0.04891156
16899357 LOXL3 1.88830211 0.03693188
16755173 PLXNC1 1.994683293 0.015575908
17019689 ENPP5 2.098588493 0.033430777
16990288 PCDHB16 2.108754723 0.014634904
16878947 LTBP1 2.282375238 0.00473262
16700806 LYST 2.446506812 0.03618726
17080082 ANGPT1 6.098613551 0.04926165
aFold change of the activated and repressed downstream target genes of
EVI1 more than 1.6-fold by match PIP1 with respect to the control.
bThe p value was calculated using t test statistics by the MeV microarray
data analysis platform. p < 0.05 is considered to be statistically signifi-
cant.
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differentially expressed genes to gain a more precise global un-
derstanding of the underlying biological processes. Interest-
ingly, in this analysis, the large number of genes corresponding
to functions such as homing of cells, metastasis, lymphoma
adhesion, and cell maturation were downregulated. EVI1 func-
tions as a survival factor and brings resistance to cell death (Liu
et al., 2006), and it also promotes cell proliferation by modu-
lating the expression of growth-stimulating factors (Go´mez-Be-
nito et al., 2010; Nayak et al., 2013). The IPA analysis of the
microarray data also revealed that most genes related to
organismal death and growth failure were upregulated to sug-
gest the role of EVI1-targeted PIP1 in inducing apoptotic cell
death and inhibiting the cellular proliferation, respectively. TheChemistry & Biology 21, 1370–1abovementioned functional annotations were highly enriched
in the genes differentially regulated by PIP1 compared with
the DMSO-treated control (Table 2). In the IPA, Z scores above
(activation) and below (inhibition) the value of two were statisti-
cally significant.
Biological Evaluation of PIP1 Reveals Antitumor
Activities
To verify whether the changes in gene expression are mani-
fested in changes in biological activity, we evaluated the ability
of PIP1 to inhibit the migration of MDA-MB-231 cells in a
scratch wound-healing assay. The DMSO-treated control tumor
cells induced the complete closure of the wound area within
24 hr, whereas treatment with PIP1 at 2 mM efficiently hindered
the migration of the breast cancer cells compared with PIP2
(Figure 5A).
To determine whether EVI1-targeted PIP1 can affect cancer
cell invasion, we performed an invasion assay by incubating
MDA-MB-231 cells with DMSO, PIP1, or PIP2 at 2 mM for
24 hr. PIP1 reduced the number of cells invading acrossMatrigel,
but DMSO and PIP2 had no significant effect on cell invasion
(Figures 5B and 5C).
An in vitro cell proliferation assay was performed to assess the
effect of PIP1 on cell growth. MDA-MB-231 cells were treated
with PIP1 at various concentrations and incubated for 72 hr.
The WST8 assay showed that PIP1 exhibited a mild range of
cytostatic activity in a concentration-dependent manner
(Figure 5D).
DISCUSSION
PIPs have the unique property of being able to recognize nucleic
acid base sequences by following the proposed DNA-recogni-
tion rule (Geierstanger et al., 1994; Trauger et al., 1996; White
et al., 1996). PIPs can bind to a specific predetermined sequence
wrapped inside nucleosomes and can influence chromatin
structure. The prospective application of PIPs in gene therapy
relies on their controlled sequence specificity (Bando et al.,
2002; Dervan, 2001; Matsuda et al., 2006; Nickols and Dervan,
2007; Nickols et al., 2013; Ueno et al., 2009; Yang et al., 2013).
Human cancer is often associated with overexpression of tumor
inducing genes; under such conditions, PIPs have the potential
use as novel antitumor agents as they can prevent the enhanced
expression of the target gene by interfering with the binding of
transcription factors to their respective regulatory sequences
without affecting the basal expression needed for the normal
cellular function (Takahashi et al., 2008). Several recent investi-
gations have focused on the antitumor properties of PIPs (Nick-
ols and Dervan, 2007; Nickols et al., 2013; Wang et al., 2010;
Yang et al., 2013).
The transcriptional activity of the highly conserved oncopro-
tein EVI1 is regulated by phosphorylation at serine 196 in its first
zinc finger domain (White et al., 2013). Elevated expression of
EVI1 results in the malignant transformation of many epithelial
cells as breast, ovarian, and pancreatic cancers (Brooks et al.,
1996; Jazaeri et al., 2010; Lugthart et al., 2008; Tanaka et al.,
2014; Patel et al., 2011). Many basal and BRCA1 associated
breast tumors have been correlated with the overexpression of
EVI1 in comparisonwith the normal breast tissue (Weber-Mangal380, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1375
Table 2. Significantly Enriched Biological Functional Annotation by IPA
Category p Value a Functions Annotationb
Predicted Activation
State
Activation Z
Scorec
Number of
Molecules
Organismal survival 7.22 3 104 organismal death increased 3.394 204
Developmental disorder 1.29 3 102 growth failure increased 2.620 56
Hematological system development and
function
3.79 3 105 quantity of blood cells decreased 3.937 104
Cellular movement 1.12 3 102 chemo taxis of cells decreased 2.778 46
6.16 3 103 homing of cells decreased 2.606 50
Cell-to-cell signaling and interaction 6.86 3 103 adhesion of lymphoma cell lines decreased 2.581 7
Cancer 2.72 3 104 metastasis decreased 2.066 65
Cellular development 4.62 3 103 maturation of cells decreased 2.050 40
aThe p value is determined by the likelihood of the number of focus genes associated with a particular biological process. p value < 0.05 is considered
to significant.
bFunctional annotation is assigned based on the literature deposited in the IPA knowledge base.
cA positive Z score suggests the potential activation, and a negative Z score refers to the potential inhibition of the particular functional process.
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ciated with reduced metastasis-free and overall survival rates of
ERa-positive subgroups of breast cancer patients. The abnormal
expression of EVI1 is the result of its genetic variants, and it may
offer resistance toward chemotherapy, resulting in the breast
cancer patient relapse (Patel et al., 2011). Recent population
studies of breast cancer patients revealed the existence of
EVI-1 rs6774494 polymorphism that is responsible for the
etiology of breast cancer (Wang et al., 2014). This aberrant
expression of EVI1 in carcinogenic conditions is governed by
the transcription factors ELK1 and RUNX1 by binding to their
respective regulatory sequences on the EVI1 minimal promoter
region (Maicas et al., 2013).
Accumulating evidence indicates that EVI1 overexpression
plays an important role inmalignancy and has prompted an inter-
est in developing inhibitors against EVI1 as targeted cancer ther-
apy. At present, small interfering RNA therapeutics is the only
available option to treat EVI1-associated diseases. However,
nucleic acid medicines have the disadvantages that they can
be degraded easily by nucleases and that they require efficient
delivery systems to reach their designated targets (Takahashi
et al., 2008). PIPs obviate these drawbacks because they can
permeate into the nuclei of living cells (Best et al., 2003) and
are highly resistant to nuclease digestion.
In our study, PIP1 (forward 50-30 binding) designed to cover
the overlapping ELK1 and REL recognition sequences on the
EVI1 promoter reduced the promoter activity by decreasing
the luciferase emission and also inhibited the expression of
EVI1. Since polyamides can also align in the reverse orientation
to the DNA (Kang et al., 2014; Meier et al., 2012b), we evaluated
the ability of a polyamide (PIP3) designed to bind in the 30-50
orientation to the target EVI1 promoter sequence (Figure S2A)
in inhibiting EVI1 expression. As expected, a significant inhibi-
tory effect of PIP3 could be observed on the EVI1 expression
(Figure S2B). Our study could contribute to the future studies
focusing on the importance of PIP binding preferences, which
in turn could aid the development of efficient PIPs for gene
regulation in targeted therapeutics. Zhang et al. (2011) previ-
ously developed polyamides to target the DNA motif recognized1376 Chemistry & Biology 21, 1370–1380, October 23, 2014 ª2014 Eby EVI1. However, in this study only the in vivo EVI1 responsive
reporter activity assay was done to prove that the polyamide
could block the binding of EVI1 to the DNA and inhibit the
EVI1 mediated transcription activity (Zhang et al., 2011). Herein,
we substantiated the scope of previous work by developing
a polyamide PIP1 capable of significantly inhibiting the expres-
sion of EVI1 itself. Furthermore, through genome-wide tran-
scriptome analysis we have demonstrated in a cell culture
model that PIP1 at a concentration of 10 mM can modulate a
fraction of EVI1-driven transcription of its target genes. These
results demonstrate that MDA-MB-231 cells effectively took
up EVI1 targeting PIP1 and that they could bind to the target
sequence, resulting in the reduction of EVI1 and its downstream
genes expression.
In the IPA analysis, the biological process enriched in the
regulated transcripts suggested that PIP1 is involved in the
negative regulation of cell movement, cell survival, and cellular
growth. The contributory role of ectopic viral integration site 1
in metastasis is supported by growing evidence. EVI1 has
been shown to contribute to the epithelial-mesenchymal transi-
tion (EMT) to promote the migration potential of breast and
ovarian cancer cells (Dutta et al., 2013). The epigenetic control
possessed by EVI1 is considered to be responsible for the
adaptation of the breast cancer cells in the metastatic sites (Pa-
tel et al., 2011). Several reports have demonstrated that EVI1
protects cells from programmed cell death (Liu et al., 2006;
Pradhan et al., 2011). Interestingly, in our experiments PIP1
targeting the ectopic viral integration site 1 reduced the cell
migration as well as induced more apoptosis (Annexin V stain-
ing; Figures S3A and S3B) when compared with the control
DMSO and mismatch polyamide PIP2. Ectopic viral integration
site 1 stimulates cell proliferation (Go´mez-Benito et al., 2010;
Nayak et al., 2013), but the level of effect completely varies be-
tween cell types (Wieser, 2007). For example, in Rat-1 fibro-
blasts, murine myeloid, and embryonic stem cells (Chakraborty
et al., 2001; Kilbey et al., 1999; Sitailo et al., 1999), EVI1 plays
an important role in controlling the cell proliferation, whereas in
REH cells, ectopic viral integration site 1 displays a weak pro-
liferative activity (Konantz et al., 2013). The mechanism of EVI1lsevier Ltd All rights reserved
Figure 5. Biological Activity of Match PIP1
(A) In vitro cell migration of the MDA-MB-231 cells.
Cells were wounded with tips of micropipette and
treated with DMSO, PIP1, and PIP2. The extent of
wound closure was photographed after 24 hr (up-
per panel at 0 hr and lower panel at 24 hr). Scale
bars represent 200 mm.
(B) In vitro invasion assay of theMDA-MB-231 cells
across the Matrigel coated membrane with or
without polyamide treatment. Scale bars represent
100 mm.
(C) Quantification of the cells migrated through the
Matrigel (p < 0.05 versus control).
(D) WST 8 assay to measure the percentage of
breast cancer cell survival after 72 hr post treat-
ment with PIP1. Values are represented as mean ±
SEM (n = 3).
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to these conflicting reports. Already reported polyamide de-
signed to inhibit the binding of EVI1 to DNA also exhibited
partial inhibition of leukemic cell growth (Zhang et al., 2011).
This context-dependent behavior of EVI1 on cell growth may
demonstrate the weak antiproliferative effects of EVI1-targeted
PIP1 even at 100 mM concentration in MDA-MB-231 cells. The
mode of action of many cancer drugs targeting DNA is nonspe-
cific, resulting in undesirable cytotoxicity and the potential
development of secondary malignant tumors (Arseneau et al.,
1972; Yang et al., 2013). Therefore, the tailor-made PIP1 could
be a promising agent in targeting EVI1 and its corresponding
context-dependent downstream effects.
While developing potent antitumor drugs, their solubility is an
important factor to be considered with respect to the adverse
toxicity. Polyamides have been reported to exhibit limited or
no cytotoxicity in mouse xenograft models and cell cultures
(Wang et al., 2010; Yang et al., 2013). However, some pyrrole-
imidazole polyamides can form aggregates at higher concentra-Chemistry & Biology 21, 1370–1380, October 23, 2014 ªtion. Thus, optimizing their structure can
improve their solubility and biological ac-
tivity (Meier et al., 2012a; Hargrove et al.,
2012). Prospective studies on the solubil-
ity and pharmacokinetic behavior of the
EVI1-targeted PIP1 will be helpful in eval-
uating its therapeutic potential.
The potential applications of these
EVI1-targeted PIPs in future therapeutics
will depend on the effects of this small
molecule in animal model experiments.
Future investigations should include
efforts to optimize the reported hairpin
PIP structures to improve their specificity
toward inhibition of EVI1 expression.
Target sequences recognized by other
transcription factors in the regulation of
ectopic viral integration site 1 expression
cannot be ruled out when designing
more effective hairpin PIPs for targeted
therapy (Warren et al., 2006). On the basis
of these findings, future studies shouldaddress the possible applications of this DNA-binding small
molecule as an effective gene silencer to treat EVI1-associated
tumorigenesis.
SIGNIFICANCE
In our study, we have developed a potent small molecule
PIP1, targeting the human ectopic viral integration site 1
(EVI1) promoter. The designed polyamide was found to
significantly reduce the EVI1 mRNA level, indicating that
PIP1 interfere with the protein binding to its regulatory
sequence. EVI1 is an oncogenic transcription regulatory pro-
tein governing awide range of potential tumor genes, and as
expected PIP1 exerted its effect on some of the EVI1-regu-
lated downstream genes like LOXL3, LTBP1, etc., which
play a major role in tumor development. In addition, PIP1 ex-
hibited potent antimetastatic properties MDA-MB-231
breast cancer cells. These results propose that PIP1 may
be a selective silencer of EVI1 and stimulates new prospects2014 Elsevier Ltd All rights reserved 1377
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recognition ability of pyrrole-imidazole polyamides.
EXPERIMENTAL PROCEDURES
Polyamide Synthesis
The synthesis of polyamides 1 to 3 was performed on a PSSM-8 peptide syn-
thesizer (Shimadzu) with a computer-assisted operation system by using
Fmoc chemistry as previously reported (Bando et al., 2002). Reaction steps
in the synthetic cycle were as follows: deblocking steps by piperidine in dime-
thylformamide (DMF); a coupling step with corresponding carboxylic acids
by 1H-Benzotriazolium 1-[bis(dimethylamino)methylene]-5chloro-,hexafluro-
phosphate (1-),3-oxide (HCTU), N,N-Diisopropylethylamine, and N-Methyl-
2-pyrrolidone (NMP); and washing steps by DMF. Each coupling reagents
in steps were prepared in DMF solution of Fmoc-Py-COOH, Fmoc-I-COOH,
Fmoc-PyIm-COOH, Fmoc-b-COOH, and Fmoc-g-COOH. All other couplings
were carried out with single-couple cycles with stirred by N2 gas bubbling.
Typically, Fmoc-Py loaded oxime-acid resin (40 mg, ca. 0.2 mmol/g,
200400 mesh) was swollen in 1 ml of DMF in a 2.5 ml plastic reaction vessel
for 30 min. Two-milliliter plastic centrifuge tubes with loading Fmoc-mono-
mers with HCTU in NMP 1 ml were placed in order position. After the comple-
tion of the syntheses on the peptide synthesizer, the resin was washed with a
mixture of methanol (2 mL) and dried in a desiccator at room temperature in
vacuum. After the cleavage from the resin by dimethylaminopropane, the
crude was purified by flash column chromatography to obtain the desired
Py-Im polyamides 1–3. Analytical high-performance liquid chromatography
and MALDI-TOF mass spectrometry was conducted to confirm the purity of
the compounds.
Cell Culture
MDA-MB-231 (breast, human) cell line was purchased from European collec-
tion of cell cultures. Cells were grown in Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL
penicillin, and 100 mg/mL streptomycin at 37C in 5% CO2 (Wang et al.,
2010).
Luciferase Assay
To determine the effect of Py-Im polyamides on EVI1 promoter, the human
EVI1-promoter-pMCS Cypridina luciferase reporter (Thermo Scientific)
chimeric plasmid was constructed to perform the luciferase reporter assay.
The primers used in the EVI1 promoter cloning are listed in Table S3.
MDA-MB-231 cells were seeded in 24-well plates at 8 3 104 cells/well.
The reported plasmid containing the EVI1 promoter (1 mg) was transfected
into the cells using FuGENE 6 transfection reagent (Promega). After 2 hr
the cells were treated with 2 mM Py-Im polyamide. The luciferase activity
was measured after 48 hr with Pierce Cypridina luciferase Flash Assay Kit
(Thermo Scientific) at 463 nm using a Spectra Max 190 (Molecular Devices)
microplate reader.
Quantitative Reverse-Transcription PCR
MDA-MB-231 cells were plated in 6-well plates at 23 105 cells/well and were
treated with various concentrations of Py-Im polyamide for 48 hr. Cells treated
with DMSO are represented as control samples. Total RNA was extracted us-
ing an RNEasy Kit (QIAGEN), and cDNA was synthesized by a ReverTra Ace
qPCR RT Kit (Toyobo) according to the manufacturer’s instructions. The ex-
pressions of mRNA were analyzed by an ABI 7300 Real Time PCR system
(Applied Biosystems) using Thunderbird SYBR q-PCRmix (Toyobo). The delta
Ct (DCt) method was used to analyze the qRT-PCR data. The expression level
of the b-actin gene was used as the internal control to normalize the target
mRNA expression. The primer list used for performing qRT-PCR is given in
the Table S3.
Microarray Analysis
MDA-MB-231 cells were plated in 6-well plates at 23 105 cells/well and were
treated for 48 hr with DMSO (0.005% control) and 10 mM concentration of
PIP1, with technical duplicates in each condition respectively. Total RNA
was prepared and the integrity of the RNA was checked using the Agilent1378 Chemistry & Biology 21, 1370–1380, October 23, 2014 ª2014 E2100 Bioanalyzer (Agilent Technologies). One hundred nanograms of total
RNA quantified by Nanodrop ND1000 v. 3.5.2 (Thermo Scientific) was labeled
using aGeneChipWTPLUSReagent kit (Affymetrix) and was hybridized to Hu-
man Gene 2.1 ST Array Strip (Affymetrix) for 20 ± 1 hr at 48C. The hybridized
arrays were washed, stained, and imaged on a GeneAtlas Personal Microarray
System (Affymetrix). The hybridized probe set values were normalized using
Affymetrix gene expression console software and analyzed for gene expres-
sion using theMultiExperiment Viewer (MeV) microarray data analysis platform
(http://www.tm4.org/mev.html). Significant differentially expressed genes be-
tween the different conditions were analyzed using t test statistics (p < 0.05).
The heatmap of the differentially regulated genes was generated using Cluster
3.0 and Java Tree View software. Microarray data reported here were depos-
ited in the Gene Expression Omnibus database under the accession number
GSE59502.
Data Analysis
Gene set enrichment analysis (GSEA; Subramanian et al., 2005) was conduct-
ed using GSEA v. 2.0.14 software to detect statistically significant PIP 1 tar-
geted genes associated with a gene set containing EVI1-regulated genes.
Data were further analyzed by IPA (Ingenuity Systems; http://www.ingenuity.
com). The IPA functional analysis was conducted to identify the significant bio-
logical functions associated with the microarray data set. Genes from the data
sets that were regulated byR1.5-fold cutoff at p < 0.05 were considered for
the analysis. The p value was calculated using right-tailed Fisher’s exact test
that defines the degree of association of the data set to the assigned biological
function.
Scratch-Wound Migration Assay
MDA-MB-231 cells were seeded in an 8-well chamber slide at 3 3 105 cells/
well. The cell layers were wounded with a large orifice plastic micropipette in
order to measure the cell migration during wound healing. The medium with
the cell debris was removed and supplemented with 400 ml of fresh medium
containing 2 mM Py-Im polyamide. Cells treated with DMSO (0.005%) were
used as control. Diff-Quik solution (Kokusaishiyaku) was used to stain the cells
at 24 hr after wounding and images were captured by phase-contrast micro-
scopy (Biorevo, BZ-9000, Keyence).
Matrigel Invasion Assay
BioCoat Matrigel Invasion Chambers (BD Bioscience) comprising transwell
(8-mm pore-sized membranes coated with Matrigel) filter inserts in a 24-well
tissue culture plate were used to evaluate cell invasion. The upper chamber
was placed with MDA-MB-231 (5 3 104 cells/well) suspended in 300 ml of
DMEM medium + 0.1% FBS containing 2 mM concentration of PIPs and
700 ml DMEM medium containing 5% FBS was added in the lower well. After
24 hr of incubation the noninvaded cells on the upper surface of the filter were
wiped out with a cotton swab, and cells that invaded across the Matrigel were
fixed and visualized using Diff-Quik solution staining.
In Vitro Cell Proliferation
MDA-MB-231 cells were seeded on 96-well microplates (5 3 103 cells/well)
and treated with diverse concentrations of PIPs and then incubated for 72 hr
at 37C in 5% CO2. Count Reagent SF (Nacalai Tesque) was added to each
well to evaluate the cell proliferation. The absorbance of each well was
measured at 450 nm by an MPR-A4iII (Tosoh) microplate reader (Wang
et al., 2010).
Apoptosis Detection Assay
The apoptosis detection assay was performed using an Apoptotic, Necrotic,
and Healthy Cells Detection Kit (Promokine) according to manufacturer’s
instructions. MDA-MB-231 cells were cultured in 8-well chamber slides at a
density of 2 3 104 cells/well and treated with 2 mM Py-Im polyamide for
48 hr. The cells were washed with a binding buffer and stained with FITC-An-
nexin V, Ethidium Homodimer III, and Hoechst 33342 (Firat et al., 2012);
then they were subjected to fluorescence microscopy analysis (Biorevo,
BZ-9000, Keyence), and the images were processed by BZ-II analyzer soft-
ware. The percentage of apoptotic cells were calculated by the number of An-
nexin V positive cells/total number of cells 3 100.lsevier Ltd All rights reserved
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Results are expressed as mean values ± SEM. Statistical significance was
determined by one-way ANOVA, followed by the Tukey’s multiple comparison
test. The p values less than 0.05 were considered to be significant.
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